

Annex One: Document containing tables 4, 5 and 6 of the Coronavirus vaccine - weekly summary of Yellow Card reporting

5th April 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the Oxford University/AstraZeneca vaccine in the UK up to and including 5 April 2021.

Country	Number of reports
England	86
Wales	2
Northern Ireland	2
Scotland	7
Unknown	3

14th April 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the Oxford University/AstraZeneca vaccine in the UK up to and including 14 April 2021.

Country	Number of reports
England	143
Wales	2
Northern Ireland	4
Scotland	12
Unknown	7

21st April 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the Oxford University/AstraZeneca vaccine in the UK up to and including 21 April 2021.

Country	Number of reports
England	169
Wales	7
Northern Ireland	5
Scotland	16
Unknown	12

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 21 April 2021.

Age range (years)	Number of reports	Number of fatal reports
18 -29	24	6
30-39	28	8
40-49	30	4
50-59	59	12
60-69	31	6
70-79	20	3
80-89	5	2
90-99	1	0
Unknown	11	0

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 21 April 2021.

Sex	Number of reports	Number of fatal reports
Male	89	17
Female	120	24

28th April 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 28 April 2021.

Country	Number of reports
England	198
Wales	9
Northern Ireland	5
Scotland	18
Unknown	12

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 28 April 2021.

Age range (years)	Number of reports	Number of fatal reports
18 -29	24	6
30-39	31	8
40-49	38	7
50-59	68	15
60-69	36	8
70-79	25	4
80-89	5	1
90-99	1	0
Unknown	14	0
Total	242	49

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 28 April 2021.

Sex	Number of reports	Number of fatal reports
Male	100	17
Female	141	32
Unknown	1	0
Total	242	49

5th May 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 05 May 2021.

Country	Number of reports
England	216
Wales	10
Northern Ireland	5
Scotland	21
Unknown	10

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 05 May 2021.

Age range (years)	Number of reports	Number of fatal reports
18 -29	25	7
30-39	33	9
40-49	46	7
50-59	70	15
60-69	41	8
70-79	26	4
80-89	5	1
90-99	1	0
Unknown	15	0
Total	262	51

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 05 May 2021.

Sex	Number of reports	Number of fatal reports
Male	112	18
Female	149	33
Unknown	1	0
Total	262	51

12th May 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 12 May 2021.

Country	Number of reports
England	243
Wales	14
Northern Ireland	7
Scotland	25
Unknown	20

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 12 May 2021.

Age range (years)	Number of reports	Number of fatal reports
18 -29	26	7
30-39	40	8
40-49	63	8
50-59	79	18
60-69	46	9
70-79	32	4
80-89	5	1
90-99	1	0
Unknown	17	1
Total	309	56

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 12 May 2021.

Sex	Number of reports	Number of fatal reports
Male	138	22
Female	169	34
Unknown	2	0
Total	309	56

19th May 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 19 May 2021.

Country	Number of reports
England	263
Wales	14
Northern Ireland	7
Scotland	27
Unknown	21

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 19 May 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	41	9
40-49	69	7
50-59	86	18
60-69	51	10
70-79	34	4
80-89	5	1
90-99	1	0
Unknown	18	2
Total	332	58

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 19 May 2021.

Sex	Number of reports	Number of fatal reports
Male	151	24
Female	180	34
Unknown	1	0
Total	332	58

26th May 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 26 May 2021.

Country	Number of reports
England	278
Wales	14
Northern Ireland	7
Scotland	28
Unknown	21

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 26 May 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	43	9
40-49	81	9
50-59	86	18
60-69	51	10
70-79	35	5
80-89	5	1
90-99	1	0
Unknown	19	2
Total	348	61

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 26 May 2021.

Sex	Number of reports	Number of fatal reports
Male	156	26
Female	189	35
Unknown	3	0
Total	348	61

2nd June 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 2 June 2021.

Country	Number of reports
England	295
Wales	14
Northern Ireland	7
Scotland	32
Unknown	24

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 2 June 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	46	10
40-49	94	10
50-59	90	20
60-69	53	10
70-79	36	5
80-89	5	1
90-99	1	0
Unknown	20	3
Total	372	66

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 2 June 2021.

Sex	Number of reports	Number of fatal reports
Male	169	27
Female	200	39
Unknown	3	0
Total	372	66

9th June 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 9 June 2021.

Country	Number of reports
England	308
Wales	14
Northern Ireland	9
Scotland	33
Unknown	26

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 9 June 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	49	11
40-49	99	12
50-59	94	20
60-69	54	10
70-79	38	7
80-89	5	1
90-99	1	0
Unknown	23	3
Total	390	71

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 9 June 2021.

Sex	Number of reports	Number of fatal reports
Male	180	29
Female	207	42
Unknown	3	0
Total	390	71

16th June 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 16 June 2021.

Country	Number of reports
England	310
Wales	13
Northern Ireland	9
Scotland	33
Unknown	24

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 16 June 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	6
30-39	49	11
40-49	97	11
50-59	93	19
60-69	56	10
70-79	38	7
80-89	5	1
90-99	1	0
Unknown	23	3
Total	389	68

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 16 June 2021.

Sex	Number of reports	Number of fatal reports
Male	183	29
Female	203	39
Unknown	3	0
Total	389	69

23rd June 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 23 June 2021.

Country	Number of reports
England	315
Wales	13
Northern Ireland	9
Scotland	32
Unknown	26

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 23 June 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	48	11
40-49	99	11
50-59	93	19
60-69	55	10
70-79	40	7
80-89	6	2
90-99	1	0
Unknown	26	3
Total	395	70

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 23 June 2021.

Sex	Number of reports	Number of fatal reports
Male	186	30
Female	206	40
Unknown	3	0
Total	395	70

30th June 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 30 June 2021.

Country	Number of reports
England	318
Wales	13
Northern Ireland	10
Scotland	33
Unknown	25

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 30 June 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	49	11
40-49	99	11
50-59	93	19
60-69	57	10
70-79	40	7
80-89	6	2
90-99	2	1
Unknown	26	3
Total	399	71

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 30 June 2021.

Sex	Number of reports	Number of fatal reports
Male	189	31
Female	207	40
Unknown	3	0
Total	399	71

7th July 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 7 July 2021.

Country	Number of reports
England	321
Wales	13
Northern Ireland	10
Scotland	34
Unknown	27

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 7 July 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	29	9
30-39	49	11
40-49	100	11
50-59	95	20
60-69	57	10
70-79	39	7
80-89	6	2
90-99	2	1
Unknown	28	3
Total	405	74

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 7 July 2021.

Sex	Number of reports	Number of fatal reports
Male	195	34
Female	208	40
Unknown	2	0
Total	405	74

14th July 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 14 July 2021.

Country	Number of reports
England	326
Wales	12
Northern Ireland	10
Scotland	35
Unknown	29

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 14 July 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	28	7
30-39	50	11
40-49	102	11
50-59	97	20
60-69	59	9
70-79	39	7
80-89	6	2
90-99	2	1
Unknown	28	3
Total	411	71

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 14 July 2021.

Sex	Number of reports	Number of fatal reports
Male	198	31
Female	211	40
Unknown	2	0
Total	411	71

21st July 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 21 July 2021.

Country	Number of reports
England	318
Wales	12
Northern Ireland	10
Scotland	34
Unknown	43

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 21 July 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	51	11
40-49	103	12
50-59	97	21
60-69	59	9
70-79	39	7
80-89	6	2
90-99	2	1
Unknown	27	3
Total	411	73

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 21 July 2021.

Sex	Number of reports	Number of fatal reports
Male	198	31
Female	211	42
Unknown	2	0
Total	411	73

28th July 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 28 July 2021.

Country	Number of reports
England	325
Wales	12
Northern Ireland	10
Scotland	35
Unknown	29

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 28 July 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	50	11
40-49	105	12
50-59	96	20
60-69	59	9
70-79	39	7
80-89	6	3
90-99	2	1
Unknown	27	3
Total	411	73

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 28 July 2021.

Sex	Number of reports	Number of fatal reports
Male	198	32
Female	211	41
Unknown	2	0
Total	411	73

4th August 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 4 August 2021.

Country	Number of reports
England	325
Wales	12
Northern Ireland	10
Scotland	35
Unknown	30

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 4 August 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	50	11
40-49	103	12
50-59	99	20
60-69	59	9
70-79	39	7
80-89	6	3
90-99	2	1
Unknown	27	3
Total	412	73

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 4 August 2021.

Sex	Number of reports	Number of fatal reports
Male	200	32
Female	210	41
Unknown	2	0
Total	412	73

11th August 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 11 August 2021.

Country	Number of reports
England	325
Wales	12
Northern Ireland	10
Scotland	35
Unknown	30

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 11 August 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	27	7
30-39	50	11
40-49	103	12
50-59	99	20
60-69	59	9
70-79	39	7
80-89	6	3
90-99	2	1
Unknown	27	3
Total	412	73

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 11 August 2021.

Sex	Number of reports	Number of fatal reports
Male	200	32
Female	210	41
Unknown	2	0
Total	412	73

18th August 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 18 August 2021.

Country	Number of reports
England	326
Wales	13
Northern Ireland	10
Scotland	35
Unknown	33

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 18 August 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	28	7
30-39	52	11
40-49	104	12
50-59	99	19
60-69	60	9
70-79	39	7
80-89	6	3
90-99	2	1
Unknown	27	3
Total	417	72

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 18 August 2021.

Sex	Number of reports	Number of fatal reports
Male	203	31
Female	210	41
Unknown	4	0
Total	417	72

25th August 2021

Table 4: Number of suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca in the UK up to and including 25 August 2021.

Country	Number of reports
England	326
Wales	13
Northern Ireland	10
Scotland	35
Unknown	31

Table 5: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient age up to and including 25 August 2021.

Age range (years)	Number of reports	Number of fatal reports
18-29	28	7
30-39	50	11
40-49	104	12
50-59	99	19
60-69	60	9
70-79	39	7
80-89	6	3
90-99	2	1
Unknown	27	3
Total	415	72

Table 6: Number of UK suspected thrombo-embolic events with concurrent thrombocytopenia ADR reports received for the COVID-19 Vaccine AstraZeneca by patient sex up to and including 25 August 2021.

Sex	Number of reports	Number of fatal reports
Male	202	31
Female	209	41
Unknown	4	0
Total	415	72